Germany-based Boehringer Ingelheim has signed a collaboration and license agreement with Yuhan, a South Korean pharma company, it was reported yesterday.
The contract has been signed for Yuhan's fusion protein for the treatment of Nonalcoholic Steatohepatitis (NASH) and related liver diseases. The fusion protein uses the HyFc technology of Genexine. It has been developed in-house by the South Korean pharma company.
The deal is valued at up to USD870m. Under the terms of the contract, Yuhan will be paid USD40m in upfront and near term payments by the German pharma company. Additionally, the company will be entitled to be paid up to USD830m in potential milestone payments and tiered royalties on net sales in the future.
The fusion protein is a dual agonist that integrates GLP-1 and FGF21 activity. It is likely to decrease liver cell injury and also hepatic inflammation through resolution of steatohepatitis. The partnership integrates Yuhan's expertise in FGF21 biology, obesity and NASH, with the pharmaceutical expertise and commitment of Boehringer Ingelheim to develop drugs for cardiometabolic diseases.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007